Future Healthcare is an annual event taking place in London, UK. It is a showcase of healthcare space international innovation. More than 350 brands attended this year. As always, heavily featured data and how experts manipulate them. Companies also tried to reinvent old technologies using a fresh approach, however.
Today, Alzheimer’s disease is one of the leading causes of death in the United States — the most common form of dementia. As the average age of the population rises slowly, the number of dementia-related deaths is likely to rise in line.
Despite this, it remains challenging to catch dementia early. Oxford Brain Diagnostics believe that years before symptoms become apparent, their technology can catch the condition.
Their secret is the measurement of cortical disarray (CDM). In short, this technique allows scientists to gather from existing MRI scans an “extra level of detail.” This enables them to detect changes in the brain’s microanatomy.
Dr. Steven Chance, CEO of Oxford Brain Diagnostics, said that “CDM extracts information on the microscopic gray matter structure of the brain by applying a unique analysis to a standard MRI scan.Even in the early stages of the disease, the method reveals the damage to the cerebral cortex because it is sensitive to cellular scale disruption.”
In addition to the obvious advantages of earlier spotting the signs of dementia, the technology could also help the pharmaceutical industry: researchers could quantify how experimental drugs affect the brain’s microstructure.